Adaptive Biotechnologies ADPT Cash Flow Statement (2018-2026)

NASDAQ ADPT
$27.98 +1.15 (+4.29%)
At close: Nov 6, 2026 · 4:00 PM EST
Reported Financials

Adaptive Biotechnologies Quarterly Cash Flow Statement

Periods 34 quarters
Latest Sep 2026

Adaptive Biotechnologies reported cash from operations of $9.61M and free cash flow of $7.68M for the quarter ended Sep 2026, up 234.8% year over year. This cash flow statement covers 34 quarters of results from Jun 2018 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-61.36M-62.80M-52.08M-45.32M-40.17M-57.70M-47.81M-50.33M-69.47M-47.53M-46.25M-32.10M-33.72M-29.83M-25.59M9.55M-13.58M-20.02M-39.94M2.81M
Depreciation and DepletionDep. & Depletion
4.47M4.64M4.77M4.96M4.86M5.00M5.23M5.34M4.96M4.79M4.58M4.16M4.07M4.31M4.08M3.98M3.77M3.42M3.27M3.18M
Depreciation, Depletion & Amortization
Amortization of IntangiblesAmort. of Intangibles
0.43M0.42M0.42M0.43M0.43M0.42M0.42M0.43M0.43M0.42M0.42M0.43M0.43M0.42M0.42M0.43M0.43M0.42M0.42M0.43M
Depreciation & Amortization (CF)Dep. & Amort.
4.47M4.64M4.77M4.96M4.86M5.00M5.23M5.34M4.96M5.21M4.57M4.16M3.93M4.29M4.07M3.97M3.65M3.39M3.24M3.14M
Share-based CompensationStock Comp.
11.88M12.86M14.18M14.14M14.29M14.67M17.35M15.34M15.56M14.30M12.96M13.52M12.83M12.15M13.36M13.26M12.72M11.93M11.12M10.39M
Gains from Sales and DivestituresGains Divest
Asset Writedowns and ImpairmentWritedown
-0.10M0.06M0.56M0.35M
Cash from Restructuring
0.68M0.19M0.09M0.64M
Other non-cash itemsOther Non-Cash
1.70M1.77M4.58M2.35M2.14M4.54M-0.90M7.52M-4.06M2.62M3.06M1.94M-2.21M1.39M1.30M0.29M2.97M1.46M1.01M1.03M
Change in Working Capital
Change in ReceivablesChange Receivables
0.29M5.11M1.19M2.84M13.51M-9.09M0.62M-0.33M6.77M4.05M-6.41M5.20M0.90M1.86M0.70M0.54M5.54M-2.05M1.20M17.16M
Change in InventoryChange Inventory
1.03M1.74M0.55M-0.07M-3.03M6.61M-0.07M0.27M-3.98M-1.11M0.82M-1.70M-3.38M-0.26M-0.10M1.35M0.01M1.32M-0.56M-0.49M
Change in Accrued ExpensesChange Accrued Exp.
-1.58M-7.55M-1.41M5.54M10.53M-15.88M7.94M-2.81M5.34M-3.94M0.41M-0.06M4.26M-9.67M3.27M5.90M1.17M-7.51M1.01M5.22M
Change in Other Operating AssetsOther Assets Change
-3.53M-0.96M0.32M0.04M-2.95M0.35M-0.72M4.33M-2.03M-1.52M1.00M1.40M-0.96M-0.49M0.50M2.52M-0.80M0.82M1.70M1.45M
Change in Other Operating LiabilitiesOther Liabilities Change
-11.38M-10.81M-13.36M-19.84M-12.48M-8.49M-5.42M-9.28M-6.11M-2.39M0.04M-6.43M-1.69M-3.33M-4.29M-32.79M3.66M4.00M3.66M6.54M
Other Working Capital ChangesOther WC Changes
1.41M-2.04M2.75M2.33M1.01M2.22M2.24M2.23M1.99M2.55M2.24M1.63M2.97M2.04M3.20M2.57M2.66M2.60M2.01M2.04M
Cash from OperationsCash from Ops.
-53.83M-64.45M-47.07M-42.41M-30.02M-59.15M-23.56M-46.68M-26.93M-38.35M-17.30M-27.07M-12.49M-28.48M-12.43M-7.13M2.06M-9.54M-6.40M9.61M
Investing Activities
Capital ExpendituresCapex
9.25M3.08M5.30M5.43M2.54M2.92M3.70M2.78M1.30M1.51M1.73M0.34M0.08M1.26M0.66M0.41M0.64M0.80M1.18M1.93M
Change in Property, Plant and EquipmentChange in PP&E
-9.25M-3.08M-5.30M-5.43M-2.54M-2.92M-3.70M-2.78M-1.30M-1.51M-1.73M-0.34M-0.08M-1.26M-0.66M-0.41M-0.64M-0.80M-1.18M-1.93M
Purchase of InvestmentsInvestments Purchased
78.54M60.24M24.96M28.55M165.03M89.10M99.38M119.08M122.00M53.48M82.72M63.26M44.80M50.65M51.14M33.19M46.73M38.86M82.73M164.98M
Sale and Maturity of InvestmentsInvestments Sold
155.00M101.00M35.00M92.00M70.03M155.00M140.40M148.00M126.50M99.50M90.33M68.89M67.00M77.49M55.14M50.88M39.12M48.80M40.43M41.85M
Cash from Investing ActivitiesCash from Investing
67.21M37.69M4.75M58.02M-97.54M62.98M37.32M26.14M3.21M44.51M5.88M5.29M22.12M25.57M3.35M17.28M-8.25M9.14M-43.48M-125.06M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
-0.68M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-0.68M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.68M
Change in Capital Stock
Common Stock IssuedStock Issued
21.85M
Net Shares Issued and RepurchasedNet Shares Issued
21.85M
Net Equity Issued and RepurchasedNet Equity Issued
21.85M
Other financing activities (as filed)
-0.32M
Cash from Financing ActivitiesCash from Financing
21.17M
Additional items
Change in Cash
-94.28M
Ending Cash Balance
78.32M
Free Cash FlowFCF
7.68M
Net Cash FlowNCF
-94.28M
Interest Paid
2.76M1.88M2.45M1.90M2.29M2.09M2.16M2.32M2.37M2.62M2.94M4.70M3.58M12.37M

Adaptive Biotechnologies Cash Flow Statement API

Pull Adaptive Biotechnologies's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ADPT&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY